| Regulatory T Cells in Cancer Immunotherapy: Basic Research Outcomes and Clinical Directions | |
| Zeng, Guoming1,2; Jin, Libo3,4,5; Ying, Qinsi6; Chen, Haojie3; Thembinkosi, Murinda Charmaine3; Yang, Chunguang7; Zhao, Jinlong7; Ji, Hao3; Lin, Sue3; Peng, Renyi3; Zhang, Maolan1,3; Sun, Da3 | |
| Corresponding Author | Zhang, Maolan(zml@cqu.edu.cn) ; Sun, Da(sunday@wzu.edu.cn) |
| 2020 | |
| Source Publication | CANCER MANAGEMENT AND RESEARCH
 |
| ISSN | 1179-1322 |
| Volume | 12Pages:10411-10421 |
| Abstract | Cancer immunotherapy is a promising approach that has recently gained its importance in treating cancer. Despite various approaches of immunotherapies being used to target cancer cells, they are either not effective against all types of cancer or for all patients. Although efforts are being made to improve the cancer immunotherapy in all possible ways, one important hindrance that lowers the immune response to kill cancer cells is the infiltration of Regulatory T (Treg) cells into the tumor cells, favoring tumor progression, on one hand, and inhibiting the activation of T cells to respond to cancer cells, on the other hand. Therefore, new anti-cancer drugs and vaccines fail to show promising results against cancer. This is due to the infiltration of Treg cells into the tumor region and suppression of anti-cancer activity. Thus, regardless of various types of immunotherapies being practiced, understanding the mechanisms of how Treg cells favor tumor progression and inhibition of anti-cancer activity is worthwhile. Therefore, the review highlights the importance of Tregs cells and how depletion of Treg cells can pave the way to an effective immunotherapy by activating the immune responses against cancer. |
| Keyword | cancer immunotherapy Treg cells FoxP3 targeting Treg cells anti-cancer |
| Funding Organization | Natural Science Foundation of Zhejiang Province ; National Natural Science Foundation of China ; Shenzhen Science and Technology Research Funding ; Special project of basic research and frontier exploration in Chongqing |
| DOI | 10.2147/CMAR.S265828 |
| Indexed By | SCI |
| Language | 英语 |
| Funding Project | Natural Science Foundation of Zhejiang Province[Q19E010021] ; Natural Science Foundation of Zhejiang Province[LQ20C020003] ; Natural Science Foundation of Zhejiang Province[LQ20C200015] ; National Natural Science Foundation of China[51901160] ; National Natural Science Foundation of China[51808086] ; Shenzhen Science and Technology Research Funding[JCYJ20160608153641020] ; Special project of basic research and frontier exploration in Chongqing[cstc2018jcyjAX0078] |
| WOS Research Area | Oncology |
| WOS Subject | Oncology |
| WOS ID | WOS:000579720000004 |
| Publisher | DOVE MEDICAL PRESS LTD |
| Citation statistics | |
| Document Type | 期刊论文 |
| Identifier | http://ir.imr.ac.cn/handle/321006/140957 |
| Collection | 中国科学院金属研究所 |
| Corresponding Author | Zhang, Maolan; Sun, Da |
| Affiliation | 1.Chongqing Univ Sci & Technol, Chongqing 401331, Peoples R China 2.China Met Construct Engn Grp Co Ltd, Chongqing 400044, Peoples R China 3.Wenzhou Univ, Inst Life Sci, Higher Educ Pk, Wenzhou 325035, Zhejiang, Peoples R China 4.Biomed Collaborat Innovat Ctr Zhejiang Prov, Wenzhou 325035, Zhejiang, Peoples R China 5.Biomed Collaborat Innovat Ctr Wenzhou, Engn Lab Zhejiang Prov Pharmaceut Dev Growth Fact, Wenzhou 325035, Zhejiang, Peoples R China 6.Univ Chinese Acad Sci, Wenzhou Inst, Wenzhou 325035, Zhejiang, Peoples R China 7.Chinese Acad Sci, Inst Met Res, Shenyang 110016, Liaoning, Peoples R China |
| Recommended Citation GB/T 7714 | Zeng, Guoming,Jin, Libo,Ying, Qinsi,et al. Regulatory T Cells in Cancer Immunotherapy: Basic Research Outcomes and Clinical Directions[J]. CANCER MANAGEMENT AND RESEARCH,2020,12:10411-10421. |
| APA | Zeng, Guoming.,Jin, Libo.,Ying, Qinsi.,Chen, Haojie.,Thembinkosi, Murinda Charmaine.,...&Sun, Da.(2020).Regulatory T Cells in Cancer Immunotherapy: Basic Research Outcomes and Clinical Directions.CANCER MANAGEMENT AND RESEARCH,12,10411-10421. |
| MLA | Zeng, Guoming,et al."Regulatory T Cells in Cancer Immunotherapy: Basic Research Outcomes and Clinical Directions".CANCER MANAGEMENT AND RESEARCH 12(2020):10411-10421. |
| Files in This Item: | There are no files associated with this item. | |||||
Items in the repository are protected by copyright, with all rights reserved, unless otherwise indicated.
Edit Comment